5-Amino-1MQ

The honest framing of the 5-Amino-1MQ literature is that the mechanism is plausible, the preclinical signal is consistent across multiple groups, and the bridge to a biohacker taking oral 5-Amino-1MQ for body-recomposition self-experimentation is mechanism plus analogy, not evidence. There are zero published human clinical trials of 5-Amino-1MQ as of 2026. No registered trial appears in ClinicalTrials.gov. Every published efficacy claim is rodent-derived.

The most-cited rodent efficacy result comes from Neelakantan and colleagues, who treated diet-induced obese C57BL/6 mice with 5-Amino-1MQ at 20 mg/kg subcutaneously three times daily (approximately 34 mg/kg/day total) for 11 days. The treated animals lost roughly 5.1% body weight (2.0 ± 0.6 g), with epididymal white adipose tissue mass reduced by approximately 35%, adipocyte size decreased by over 30%, and plasma total cholesterol down approximately 30% — all without changes in food intake, which is mechanistically interesting because it implicates altered energy partitioning rather than appetite suppression (Neelakantan et al., Biochem Pharmacol 2018, 147:141–152). This is the pharmacological replication of the Kraus 2014 antisense-knockdown phenotype that gave the molecule its initial credibility.

A separate strand of preclinical work extends the mechanism into aged skeletal muscle. Neelakantan and colleagues, 2019 treated 24-month-old mice with NNMT inhibitor at 5 and 10 mg/kg following acute tibialis anterior injury and reported nearly two-fold greater myofiber cross-sectional area, a shift in fiber size distribution toward larger myofibers, and an approximately 70% increase in peak torque in treated animals versus controls. The proposed mechanism is reactivation of senescent muscle stem cells via restored NAD+ availability — the same metabolic logic that animates the broader NAD+ and mitochondrial peptides discussion. A 2022 follow-up by Dimet-Wiley et al., Sci Rep 2022 combined NNMT inhibition with calorie restriction in diet-induced-obese mice, reporting amplified weight loss and a distinct gut microbiome signature relative to either intervention alone.

The biohacker use case sits in three contexts: (1) as an oral adjunct to GLP-1 / GIP agonists like semaglutide and tirzepatide for the muscle-preservation problem documented across the incretin trials, (2) as a body-recomposition tool in the practitioner stack alongside MK-677, and (3) as part of the broader fat-loss decision guide. In all three contexts the same caveat applies: oral 5-Amino-1MQ in humans is mechanistically reasonable, completely uncharacterized in published trials, and rests on rodent data alone. The forthcoming sarcopenia-and-peptides dossier (see muscle preservation decision guide for the current treatment) will cover the muscle-stem-cell angle in more depth.

The pharmacokinetic gap is also worth naming explicitly. The 2018 efficacy study used subcutaneous injection in mice; published assays of oral bioavailability in rats exist but no equivalent human PK study has been published. Biohacker community use is essentially universally oral, on the assumption that the molecule is small and drug-like enough to absorb — a reasonable assumption that is not the same as a characterized AUC and Cmax in humans.